News

BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients

— Favorable safety profile of resorbable breast scaffolds in one-year follow-up

— No major scaffold-related complications or scaffold removals

— BellaSeno will initiate multicenter pivotal clinical trial with more than 100 patients

BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that 10 breast scaffold patients and 5 pectus patients have successfully passed one-year follow-up in BellaSeno´s Australian clinical trials.

Read more…

Thermosome Appoints Dr. Sabine Hauck as Chief Technical Officer

–    Experienced biopharma professional focused on drug product development

Thermosome, a drug development company focused on targeted tumor therapies, today announced the appointment of Dr. Sabine Hauck as Chief Technology Officer (CTO).

Dr. Sabine Hauck is a highly experienced biopharmaceutical professional. She has been working in the field of drug product development in biopharma and specialty pharma for more than 20 years. Notably, she brings more than a decade of experience with liposomal products. Her expertise covers process development, chemistry, manufacturing and controls as well as bioanalytics, quality management and regulatory affairs. Read more…

BellaSeno Receives Financial Support Through Queensland’s Industry Partnership Program

— Funding to support establishment of the world´s first fully automated production facility for resorbable medical scaffolds based in Australia

— AI-driven, no-touch manufacturing to ensure highest quality, safety and sterility levels

— Designed to manufacture up to 100,000 scaffolds per annum at full capacity

BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced today that its Australian subsidiary has received financial assistance through the Queensland Government’s Industry Partnership Program.

Read more…

selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis

— New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity

— Recruitment is underway, with topline results expected in 4Q24

selectION, Inc. (“selectION” or the “Company”), a clinical-stage biopharmaceutical company developing novel treatments for T cell-mediated autoimmune diseases, today announced the initiation of a Phase 1b trial with its lead compound si-544 in adult patients with psoriasis vulgaris (Ps) or psoriatic arthritis (PsA). Read more…

1 2 190